A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.

Por Vokes, E. E., Mick, R., Vogelzang, N. J., Geiser, R., Douglas, F.
Publicado em 1990

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

Por Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.
Publicado no Ann Oncol (2016)

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Por Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M. W., Parker, C.
Publicado no Ann Oncol (2017)

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analys...

Por Scosyrev, E., Ely, B.W., Messing, E.M., Speights, V.O., Grossman, H. B., Wood, D.P., de Vere White, R.W., Vogelzang, N.J., Trump, D.L., Natale, R.B., Tangen, C., Crawford, E.D., Thompson, I.M.
Publicado em 2010

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Por Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Publicado no Ann Oncol (2016)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Por Fradet, Y, Bellmunt, J, Vaughn, D J, Lee, J L, Fong, L, Vogelzang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Necchi, A, Gerritsen, W, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, Frenkl, T L, Perini, R F, de Wit, R, Bajorin, D F
Publicado no Ann Oncol (2019)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Por Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F.
Publicado no N Engl J Med (2017)